<DOC>
	<DOCNO>NCT01745133</DOCNO>
	<brief_summary>The purpose study investigate combine use OLUX-E™ Foam SORILUX Foam may help `` maintain '' therapeutic benefit achieve OLUX-E™ Foam treatment moderate plaque psoriasis . OLUX-E™ medication contains corticosteroid deliver foam formulation . SORILUX Foam foam formulation calcipotriene . Both medication approve FDA treat plaque psoriasis .</brief_summary>
	<brief_title>Olux E Foam Sorilux Foam Combination Therapy Maintenance Treatment Response Patients With Moderate Plaque Psoriasis</brief_title>
	<detailed_description>This single-center , investigator-blind study . Approximately 60 qualified subject enrol 2 week treatment phase receive 2 week treatment Olux E foam . After 2 week treatment , subject PGA 0 1 re-randomized maintenance phase . Subjects achieve PGA score &gt; 2 discontinue study randomize . Subjects achieve PGA score 0 1 enter 8 week maintenance phase randomize 1:1:1 basis one follow treatment group : - Vehicle foam ( BID ) - Sorilux foam ( BID ) - Sorilux foam ( BID weekdays ) + Olux E foam ( BID weekend ) Subjects attend clinic visit week 6 . At week 10 study treatment stop . The maximum duration study 10 week consist Screening/Baseline Visit ( Week -0 ) , Re-randomization maintenance phase visit ( Week 2 ) , treatment follow-up visit Weeks 6 , end treatment visit week 10 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Outpatient , male female subject race , 18 year age high . Female subject childbearing potential must negative urine pregnancy test within 7 day prior first dose study drug practice reliable method contraception throughout study [ Exception : Female subject child bear potential sexually active require practice reliable method contraception may enrol Investigator 's discretion provide counseled remain sexually inactive duration study understand risk involve get pregnant study . ] Moderate plaque type psoriasis eligible topical therapy . A Bod Surface Area ( BSA ) 310 % . Physician Global Assessment ( PGA ) score 3 . Able understand study requirement sign Informed Consent/Health Insurance Portability Accountability Act form . Female subject pregnant , breastfeeding , childbearing potential practicing reliable method birth control , male subject plan pregnancy spouse partner study . History hypocalcaemia vitamin D toxicity . Serious skin condition ( psoriasis ) uncontrolled medical condition ( opinion investigator ) . Topical steroid , topical immunomodulators , topical vitamin D derivative , tar , salicylic acid , anthralin topical treatment psoriasis within 2 week baseline . Use biologics within 3 month baseline . Use systemic psoriasis treatment ( ie , oral retinoids , methotrexate , cyclosporine , immunomodulators ) within 4 week baseline . Use Ultraviolet B light ( UVB ) oral psoralen ultraviolet A ( PUVA ) within 2 week baseline . Skin condition ( e.g . eczema ) psoriasis may interfere evaluation psoriasis . Known hypersensitivity Sorilux Foam Ointment component . Known hypersensitivity Olux E Foam component . Contraindications accord Sorilux Foam Olux E Foam package insert . Current drug alcohol abuse ( Investigator opinion ) . Subject unable commit assessment require protocol . Current enrollment another clinical study treatment another experimental drug approve therapy experimental use within 30 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Olux E foam</keyword>
	<keyword>Sorilux foam</keyword>
</DOC>